Find a Physician | How to Contribute | About Us | Clinical Trials
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial SWOG 1001

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)
Principal Investigator
Jason Kaplan
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.SWOG 1001
Limited (or early) Stage Diffuse Large B-cell Lymphoma (DLBCL) is curable in many people, but some still relapse, and some develop side-effects after treatment. This study uses a radiologic test called PET/CT scan after initial standard chemotherapy (R-CHOP) to help individualize subsequent treatment in the hope of improving cure rates while decreasing side effects of treatment.
Standard chemotherapy "R-CHOP" for DLBCL will be followed up with a full body PET/CT scan to determine if there is active disease. If the PET/CT scan shows active lymphoma then those participants will receive more intensive treatment than those who have inactive disease after chemotherapy.
Some of the eligibility criteria include:
  • Participant's diagnosis of Diffuse Large B-cell Lymphoma must have been proven by biopsy.
  • Participants must be 18 years old or older.
  • Participants must not have received prior chemotherapy, radiation or antibody therapy for lymphoma.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants will receive 3 cycles (21 days each) of standard chemotherapy called "R-CHOP" (FDA approved drugs doxorubicin, cyclophosphamide, vincristine, prednisone and rituximab). After completing the 3 cycles of chemotherapy, participants will have a full body PET/CT scan. If the review of the PET/CT scan shows that disease is likely inactive, participants will receive an additional cycle (21 days) of R-CHOP for consolidation. If the review of the PET/CT scan shows that disease may still be active, then participants will receive radiation therapy to areas of the body with evidence of lymphoma, followed by a drug regimen called Yttrium-90 ibritumomab tiuxetan (Zevalin®). Follow-up visits will be every 6 months for 2 years and then yearly for a maximum of 7 years from the time participants entered the study.
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jason Kaplan

last updated: 27-Nov-15 02:12 AM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.